RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
Operator of a biotechnology company intended to provide services regarding the functional manipulation of immune cells. The company maps human tissue's behavior to disease processes, allowing it to identify and characterize novel targets for therapeutic intervention, enabling patients to get access to treatment and cure themselves of debilitating illnesses including cancer, fibrotic, autoimmune and inflammatory diseases.
Creating novel bispecific antibodies that activate the immune system to fight cancer
Iterative Scopes, Inc. is a Boston-based company founded in 2017 that specializes in developing machine learning-powered diagnostic tools for gastroenterologists aimed at preventing colon cancer. The company utilizes computer vision and machine learning technologies to provide real-time computer-aided detection and diagnostic tools, which enhance the ability of doctors to detect and categorize lesions during procedures. These tools are designed to improve patient outcomes by identifying lesions that may be missed by the human eye. Additionally, Iterative Scopes offers access to deep neural networks trained by experienced gastrointestinal specialists, thereby expanding the availability of advanced diagnostic capabilities for healthcare providers globally.
Verana Health, Inc. is a software company dedicated to improving the connection between healthcare providers and mobile diagnostics. Based in San Francisco, the company provides a range of tools designed to facilitate real-time access to diagnostic data for both patients and physicians. Its flagship product, SightBook, is a mobile application that allows users to assess their vision and share results with their healthcare providers instantly, while also enabling physicians to manage appointments and treatments effectively. In addition to SightBook, Verana Health offers a cloud-based portal, a smartphone application for vision assessments, mobile imaging devices, and analytics tools that support the monitoring of patient data. By partnering with leading medical associations, Verana Health transforms clinical data into actionable insights, helping to accelerate medical research and improve patient care. The company was previously known as Digisight Technologies, Inc. before rebranding in July 2018 and has been operational since its incorporation in 2008.
AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
Mauna Kea Technologies SA is a medical device company headquartered in Paris, France, specializing in the development and marketing of imaging technologies for the diagnosis and treatment of cancer and other diseases. Its primary product, Cellvizio, is a confocal laser endomicroscopy platform that allows real-time, in vivo microscopic visualization of tissues at the cellular level. This technology aids physicians in accurately detecting early-stage pathologies and making informed therapeutic decisions. The company operates globally, with a significant presence in Europe, the United States, and various countries in Asia and Latin America. Mauna Kea Technologies generates revenue primarily from the sales of Cellvizio products and related accessories used in medical diagnostics and research.
FlexDex Inc. specializes in the development of minimally invasive surgery (MIS) devices, focusing on enhancing surgical precision and dexterity. The company's innovative platform technology allows surgeons to translate their hand, wrist, and arm movements from outside the patient into corresponding movements of an end-effector within the patient's body. This capability improves the functionality of MIS instruments and endoscopes, making procedures safer and more efficient. FlexDex serves healthcare professionals through a network of distributors both in the United States and internationally. Founded in 2010 and based in Brighton, Michigan, FlexDex continues to advance the field of minimally invasive surgery.
Visus Therapeutics is a clinical-stage company focused on developing innovative ophthalmic therapies aimed at enhancing vision for individuals globally. The company is known for its presbyopia-correcting eye drops, which are designed to provide temporary relief from the loss of near vision associated with presbyopia. Additionally, Visus Therapeutics is engaged in the development of various ophthalmic product candidates targeting conditions such as ocular surface disease, glaucoma, and age-related macular degeneration. Through its research and product offerings, the company seeks to address significant unmet needs in vision care.
Iterative Scopes, Inc. is a Boston-based company founded in 2017 that specializes in developing machine learning-powered diagnostic tools for gastroenterologists aimed at preventing colon cancer. The company utilizes computer vision and machine learning technologies to provide real-time computer-aided detection and diagnostic tools, which enhance the ability of doctors to detect and categorize lesions during procedures. These tools are designed to improve patient outcomes by identifying lesions that may be missed by the human eye. Additionally, Iterative Scopes offers access to deep neural networks trained by experienced gastrointestinal specialists, thereby expanding the availability of advanced diagnostic capabilities for healthcare providers globally.
POINT Biopharma Global Inc. is a globally focused radiopharmaceutical company building a platform for the clinical development and commercialization of radioligands that fight cancer. POINT Biopharma Global Inc. is combining a portfolio of best-in-class radiopharmaceutical assets, a seasoned management team, expertise in radioisotopes such as Actinium-225 (Ac-225) and Lutetium-177 (Lu-177), manufacturing technology and novel direct-to-patient targeting to revolutionize theragnostic drug development and radioligand commercialization.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
Thirty Madison, Inc. is a digital health company based in Astoria, New York, focused on providing specialized care for chronic conditions through its web-based platforms. Founded in 2016, the company operates several condition-specific brands: Keeps, which offers a subscription service for men's hair loss prevention medications; Cove, which provides online consultations and prescriptions for migraine treatment; and Evens, designed to manage acid reflux. By offering these tailored services, Thirty Madison aims to increase access to affordable healthcare solutions, addressing the unique needs of patients suffering from these conditions.
Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.
Private Equity Round in 2021
Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.
Developer of a biotechnology research and development platform designed to offer therapeutics for the treatment of cancer and inflammatory diseases. The company's platform exploits emerging insights related to the role of activated fibroblast populations in disease for developing therapeutics to interrupt fibroblast-mediated effects on immune cells in inflammatory disease and cancer, enabling the medical industry to combat and cure rare and life-threatening diseases.
Sunday2Sunday is an emerging textured hair care company that focuses on bringing ingredients and products to its customer's doorstep. It specializes in the fields of beauty, healthcare, and consumer goods. It was founded in 2019 and headquartered in Brooklyn, New York.
Visus Therapeutics is a clinical-stage company focused on developing innovative ophthalmic therapies aimed at enhancing vision for individuals globally. The company is known for its presbyopia-correcting eye drops, which are designed to provide temporary relief from the loss of near vision associated with presbyopia. Additionally, Visus Therapeutics is engaged in the development of various ophthalmic product candidates targeting conditions such as ocular surface disease, glaucoma, and age-related macular degeneration. Through its research and product offerings, the company seeks to address significant unmet needs in vision care.
TechsoMed is an Israeli based medical device company, developing ultrasound based real-time monitoring systems for thermal ablation procedures. The applications of thermal ablation are numerous: tumor destruction, heart arrhythmia, blood pressure treatments and more. The procedure has market size in the billions, but lacks real-time monitoring capabilities, causing high failure rates.
Their technology offers added value to patients, physicians and insurance companies by solving the high failure rate of these minimally invasive and cost effective procedures.
Paige builds software to advance the diagnosis, treatment, and biomarker discovery for cancer. The Memorial Sloan Kettering spin-out aims to help pathologists and clinicians make faster, more informed diagnostic and treatment decisions and to bring new digital biomarkers to their practice. Paige’s proprietary Machine Learning solutions provide insights from decades of data from the world’s experts in cancer care and were recently published in Nature Medicine. The company’s first product for prostate cancer detection received Breakthrough Designation from the FDA as a novel therapy that stands to improve diagnostic accuracy while reducing costs to health systems.
Paige builds software to advance the diagnosis, treatment, and biomarker discovery for cancer. The Memorial Sloan Kettering spin-out aims to help pathologists and clinicians make faster, more informed diagnostic and treatment decisions and to bring new digital biomarkers to their practice. Paige’s proprietary Machine Learning solutions provide insights from decades of data from the world’s experts in cancer care and were recently published in Nature Medicine. The company’s first product for prostate cancer detection received Breakthrough Designation from the FDA as a novel therapy that stands to improve diagnostic accuracy while reducing costs to health systems.
ONL Therapeutics, Inc. is a biopharmaceutical company based in Ann Arbor, Michigan, focused on developing innovative therapies aimed at protecting vision by targeting photoreceptors. Established in 2006, the company specializes in creating photoreceptor protective agents that address the FAS apoptotic pathway, which is critical for preserving photoreceptor cells. With a growing market for retinal drugs exceeding $7 billion, ONL Therapeutics aims to overcome the limitations of existing treatments that do not target the initial neural component of vision loss. The company’s drug programs include small-molecule peptides designed to protect photoreceptors during vision-threatening conditions such as retinal detachment, ultimately enhancing patient outcomes and supporting successful surgical interventions.
Datavant, Inc. is a healthcare data platform that aggregates and analyzes biomedical data using machine learning and artificial intelligence. Founded in 2017 and based in San Francisco, the company focuses on enhancing the clinical trial process by organizing and structuring healthcare data to provide actionable insights. Datavant's services cater to the clinical development and commercial pharmaceutical sectors, as well as researchers, by facilitating the protection, matching, and sharing of health data. The platform is designed to help pharmaceutical companies manage privacy, security, compliance, and trust, thereby enabling safe data sharing and improving the design and interpretation of clinical trials.
Syndesi Therapeutics SA is a biopharmaceutical company based in Louvain-la-Neuve, Belgium, founded in 2018. The company focuses on developing drug molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the process that facilitates communication between neurons in the brain. By regulating this transmission, Syndesi aims to create effective treatments for Alzheimer’s Disease and other cognitive impairment disorders. The company holds an exclusive license to its innovative platform technology from UCB, a leader in SV2A research. Through its efforts, Syndesi Therapeutics seeks to provide healthcare providers with advanced therapeutic options for managing these challenging conditions.
V-Wave Ltd. is a medical technology company based in Caesarea, Israel, with additional offices in the United States. Founded in 2009, it specializes in the development of percutaneous implantable therapeutic devices aimed at treating chronic heart failure (HF) patients, which is a major cause of morbidity and mortality worldwide. The company has created the V-Wave Shunt, a biocompatible inter-atrial unidirectional implant designed for patients with both preserved and reduced ejection fractions, addressing the needs of those who experience disabling symptoms despite optimal medical therapy. V-Wave's innovative approach focuses on relieving symptoms, reducing hospitalizations, enhancing exercise capacity, and improving overall quality of life for HF patients. The organization is backed by a team of experienced engineers and medical scientists who have a proven track record in developing and bringing various implantable cardiovascular devices to market.
Sunday2Sunday is an emerging textured hair care company that focuses on bringing ingredients and products to its customer's doorstep. It specializes in the fields of beauty, healthcare, and consumer goods. It was founded in 2019 and headquartered in Brooklyn, New York.
Aetion, Inc. develops a science and analytics platform to assess real-world evidence (RWE) from a range of sources. The company offers Aetion Evidence Platform, a platform that generates RWE needed by healthcare decision makers to engage in value-based care. Its solution allows payers, providers, medical device makers, biopharma customers, and academic institutions to analyze data from various clinical and financial interactions in healthcare, including claims, electronic health records, registries, and clinical trials. The company’s platform is also used in database analytics and comparative effectiveness courses taken by epidemiologists, outcomes researchers, health economists, and biostatisticians. It serves customers worldwide. Aetion, Inc. has a strategic collaboration with McKesson. The company was founded in 2012 and is based in New York, New York.
G.I. Windows, Inc. is a clinical-stage company based in West Bridgewater, Massachusetts, specializing in the development of surgical anastomotic technology aimed at treating obesity and type 2 diabetes. Founded in 2012, the company focuses on creating innovative solutions that facilitate less invasive surgical procedures, thereby expanding the range of available medical interventions. G.I. Windows is dedicated to improving healthcare outcomes by balancing the needs of patients with the overall efficiency of the healthcare system. Through its groundbreaking technology, the company aims to establish a new category in healthcare that not only enhances procedural effectiveness but also reduces costs associated with surgical treatments.
ImmPACT Bio USA Inc. is a cell therapy company aiming to develop potent and selective engineered T-cells for the treatment of solid tumors. The Company's technology enables targeting loss-of-gene features of solid tumor cells, sparing normal, healthy tissues.
Thirty Madison, Inc. is a digital health company based in Astoria, New York, focused on providing specialized care for chronic conditions through its web-based platforms. Founded in 2016, the company operates several condition-specific brands: Keeps, which offers a subscription service for men's hair loss prevention medications; Cove, which provides online consultations and prescriptions for migraine treatment; and Evens, designed to manage acid reflux. By offering these tailored services, Thirty Madison aims to increase access to affordable healthcare solutions, addressing the unique needs of patients suffering from these conditions.
Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.
Cue Health Inc. is a healthcare technology company based in San Diego, California, specializing in the development and manufacturing of diagnostic screening devices for home use. Founded in 2010, the company offers a connected diagnostic platform known as the Cue Health Monitoring System, which allows users to conduct self-serve tests that provide lab-quality results. This platform enables individuals to track key health indicators, including inflammation, vitamin D, fertility, influenza, and testosterone, through a user-friendly device that connects to a smartphone app. The Cue app not only displays test results but also integrates data on lifestyle factors such as activity and sleep, facilitating a comprehensive view of health at a molecular level. Additionally, Cue Health provides various services for healthcare professionals, including tools for managing patient test histories and telemedicine consultations. The company's innovative approach empowers consumers and healthcare providers alike to access critical health information easily and effectively.
HistoSonics provides the Edison Platform, which uses advanced imaging and proprietary sensing technology to deliver non-invasive, personalized treatments with precision and control, and uses the science of histotripsy and focused sound energy to generate pressures to liquify and completely destroy targeted tissues at sub-cellular levels.
GATT Technologies BV develops synthetic surgical hemostat and sealant products that control severe bleeding. The company provides products, such as GATT-Patch, a hemostatic sealing patch for general surgery; GATT-Tape, a tape for preventing intestinal anastomotic leakage; GATT-Spray, an adhesive elastic sealant for general surgery; and GATT-Powder, a hemostatic sealing powder. GATT Technologies BV was founded in 2011 and is based in Nijmegen, the Netherlands.
RefleXion Medical Inc. specializes in developing a biologically-guided radiotherapy system aimed at transforming cancer treatment. The company’s innovative technology allows tumors to continuously signal their location during therapy, facilitating the simultaneous treatment of multiple tumors, particularly in cases of metastasis. The RefleXion X1 machine is currently cleared for various forms of radiotherapy, including stereotactic body radiotherapy (SBRT) and intensity-modulated radiotherapy (IMRT). At the core of RefleXion's approach is the integration of positron-emission tomography (PET) imaging, which enables real-time tumor tracking and dose adaptation based on the biological characteristics of the tumors. This advancement in radiotherapy promises to enhance precision in cancer treatment, offering a potential paradigm shift in radiation oncology. RefleXion Medical, incorporated in 2009 and based in Hayward, California, has established strategic collaborations, including partnerships with Telix Pharmaceuticals and HealthMyne.
OrthoSpin Limited, founded in 2014 and based in Misgav, Israel, specializes in the development of an innovative robotic external fixation system designed to enhance treatment for patients with bone injuries and limb deformities. The company’s dynamic external fixators offer a significant improvement over traditional systems, which are often cumbersome and painful. OrthoSpin’s system features a lightweight motorized strut and a control box integrated into a circular hexapod fixation frame, allowing for automatic and continuous pre-programmed adjustments without requiring patient involvement. This smart system not only ensures adherence to prescribed treatment plans but also enables real-time monitoring of patient progress through proprietary software. By facilitating timely adjustments to treatment schedules, OrthoSpin aims to reduce complications and improve clinical outcomes for orthopedic patients, thereby accelerating their recovery process.
AviadoBio mission is to transform the lives of people living with neurodegenerative disorders by developing and delivering transformative gene therapies for diseases including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The Company’s technology is based on pioneering research from King’s College London and the UK Dementia Research Institute.
Mauna Kea Technologies SA is a medical device company headquartered in Paris, France, specializing in the development and marketing of imaging technologies for the diagnosis and treatment of cancer and other diseases. Its primary product, Cellvizio, is a confocal laser endomicroscopy platform that allows real-time, in vivo microscopic visualization of tissues at the cellular level. This technology aids physicians in accurately detecting early-stage pathologies and making informed therapeutic decisions. The company operates globally, with a significant presence in Europe, the United States, and various countries in Asia and Latin America. Mauna Kea Technologies generates revenue primarily from the sales of Cellvizio products and related accessories used in medical diagnostics and research.
ProteKt Therapeutics is a drug development company focused on creating potent and selective oral inhibitors of the kinase PKR to address neurodegenerative and neuroinflammatory diseases. The company has successfully developed a series of novel molecules through innovative computational methods, followed by validation in clinically relevant assays. These inhibitors aim to improve memory consolidation and enhance long-term memory in patients suffering from these conditions. ProteKt Therapeutics has raised $4 million in a pre-A funding round and is a graduate of the FutuRx accelerator, which supports emerging biotechnology ventures.
X-Vax Technology is a biotechnology company focused on the preclinical and clinical development of vaccines against pathogens that cause mucosal infections such as herpes, influenza, tuberculosis and HIV, affecting hundreds of millions of people around the globe. They believe that inducing antibodies that mediate the killing of infected cells will provoke an entirely new and effective immune response – so that they can finally beat these pathogens. The company was founded in 2015 and based in Jupiter, Florida.
Cara by HiDoc Technologies is a Berlin-based pharmaceutical company established in 2015 that focuses on empowering patients with chronic digestive diseases. The company develops digital therapeutics aimed at enhancing existing therapies for gastrointestinal disorders. Cara's primary offering is a virtual health advising application that allows users to maintain a personal food and symptom diary. This application enables patients to track their dietary choices and record symptoms such as pain and bloating, helping them identify patterns related to their health. By providing tools for self-monitoring and understanding their conditions, Cara seeks to facilitate better health management for individuals suffering from digestive issues.
BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.
TechsoMed is an Israeli based medical device company, developing ultrasound based real-time monitoring systems for thermal ablation procedures. The applications of thermal ablation are numerous: tumor destruction, heart arrhythmia, blood pressure treatments and more. The procedure has market size in the billions, but lacks real-time monitoring capabilities, causing high failure rates.
Their technology offers added value to patients, physicians and insurance companies by solving the high failure rate of these minimally invasive and cost effective procedures.
Cala Health, Inc. is a bioelectronic medicine company focused on developing innovative therapies for chronic diseases. Based in Burlingame, California, the company specializes in wearable neuromodulation devices that utilize advancements in neuroscience and technology to provide individualized peripheral nerve stimulation. Its flagship product, Cala Trio, is a non-invasive therapy designed to offer relief from hand tremors in adults with essential tremor, a condition affecting millions. In addition to its current offerings, Cala Health is actively developing new therapeutic solutions in the fields of neurology, cardiology, and psychiatry, aiming to enhance the standard of care for patients with chronic conditions. Founded in 2013, the company has garnered support from prominent investors in both the healthcare and technology sectors.
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors to further assess the anti-tumor activity, and dosing schedule and pharmacodynamics of the combinations. In addition, it is progressing its earlier-stage product candidate, FPI-1966 into clinical development for the treatment of head and neck, and bladder cancers expressing fibroblast growth factor receptor. The company was founded in 2014 and is headquartered in Hamilton, Canada.
Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.
Memebox Corporation is an online retailer specializing in beauty care products, with a strong emphasis on Asian beauty trends, particularly K-beauty. Founded in 2012 and based in San Francisco, the company offers a wide range of skincare items such as cleansers, toners, sheet masks, serums, creams, and sunscreens. Additionally, Memebox provides an extensive selection of makeup products, including foundations, eyeshadows, lip care, and nail care items. The company serves a diverse customer base across the United States, China, Korea, and other international markets, focusing on trend forecasting and creating private label products that cater to beauty enthusiasts.
Ribon Therapeutics, Inc. is a biotechnology company based in Lexington, Massachusetts, founded in 2015. The company is focused on developing innovative cancer therapies that target monoPARP proteins, which are essential regulators of cancer cell survival. Ribon's scientific founders have made significant contributions to the understanding of PARPs, or poly(ADP-ribose) polymerases, and their roles in cancer. Leveraging this expertise, Ribon is establishing a proprietary drug discovery platform aimed at exploring the molecular actions and biological functions of monoPARPs. This platform supports the creation of a pipeline of therapeutics that selectively target these proteins to potentially treat cancer and other diseases. Ribon Therapeutics is supported by notable life science investors, enhancing its capability to advance its research and development efforts.
MultiScale Health Networks LLC develops and markets cloud based data platform and application that provides real time data access to healthcare industry. The application extracts, aggregates, and optimizes operational intelligence from emergency department and share patient data across care operations. The platform provides data access to multi-disciplinary team, and allows communication and collaboration across different teams. MultiScale Health Networks LLC was founded in 2012 and is based in Seattle, Washington.
Carrot Inc. is a company based in Redwood City, California, that specializes in smoking cessation through its application, Pivot. Founded in 2015, Carrot offers a unique six-stage program that engages smokers early in their journey without imposing pressure to quit. The program begins by fostering awareness of smoking habits and enhancing confidence in the smoker's ability to change. For those who choose to pursue cessation, Pivot assists users in creating and implementing a personalized quit plan, supported by one-on-one coaching until they achieve stability in their quit journey. This approach emphasizes self-motivation and personal commitment, distinguishing Carrot's service in the field of smoking cessation.
CuraSen Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company specializes in small molecule drugs that target a novel mechanism in the brain, aiming to restore function, improve symptoms, and modify the progression of conditions such as Parkinson's disease, Alzheimer's disease, and less common orphan neurodegenerative disorders. Founded in 2016, CuraSen Therapeutics is headquartered in Los Altos, California.
PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company based in Malvern, Pennsylvania, focused on developing innovative therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor and is currently undergoing Phase III clinical trials for patients experiencing uncontrolled bleeding or requiring urgent surgery. The company is also advancing PB1046, a fusion protein aimed at treating pulmonary arterial hypertension, which is in Phase IIb clinical trials. Additionally, PhaseBio is developing PB6440, an oral agent intended for the treatment of resistant hypertension. Founded in 2002, the company leverages proprietary recombinant biopolymers to enhance the stability and efficacy of its drug candidates.
OrthoSpin Limited, founded in 2014 and based in Misgav, Israel, specializes in the development of an innovative robotic external fixation system designed to enhance treatment for patients with bone injuries and limb deformities. The company’s dynamic external fixators offer a significant improvement over traditional systems, which are often cumbersome and painful. OrthoSpin’s system features a lightweight motorized strut and a control box integrated into a circular hexapod fixation frame, allowing for automatic and continuous pre-programmed adjustments without requiring patient involvement. This smart system not only ensures adherence to prescribed treatment plans but also enables real-time monitoring of patient progress through proprietary software. By facilitating timely adjustments to treatment schedules, OrthoSpin aims to reduce complications and improve clinical outcomes for orthopedic patients, thereby accelerating their recovery process.
S-Biomedic is a Belgian biotech company specializing in live probiotic cosmetics designed to improve skin health. The company focuses on the skin microbiome, a complex ecosystem of beneficial and harmful bacteria that plays a crucial role in skin conditions such as acne, eczema, rosacea, and aging. S-Biomedic employs advanced modulation-based technology to selectively harness beneficial bacteria, creating products that promote the rebalancing of the skin microbiome. By utilizing the latest advancements in microbiology and dermatology, their offerings aim to restore healthy skin and address various dermatological concerns. Through this innovative approach, S-Biomedic provides therapeutic solutions in both the dermatology and cosmetic sectors, enhancing the overall health and beauty of the skin.
Zebra Medical Vision Ltd. is an Israeli company founded in 2014 that specializes in developing an imaging analytics platform aimed at enhancing healthcare delivery. The platform provides a comprehensive suite of imaging research solutions for clinicians, advanced machine learning and computer vision diagnostic algorithms for developers, and risk management tools for healthcare providers. By offering access to a vast repository of anonymized clinical records, Zebra Medical Vision supports researchers in accelerating the development of decision support tools and improving diagnostic accuracy. The company collaborates with various partners, including USARAD Holdings and TELUS Ventures, to leverage its network of over 1,100 hospitals and healthcare providers. This collaboration fosters innovation and enhances patient care through the application of advanced analytics and automated clinical insights, positioning Zebra Medical Vision as a leader in the integration of AI and machine learning in medical imaging.
NeuroVision Imaging LLC is a neuroscience company that specializes in digital imaging and diagnostic solutions for Alzheimer’s disease and eye care. Founded in 2010 and based in Sacramento, California, the company focuses on developing diagnostic tests and biomarkers to detect and monitor amyloid pathology associated with Alzheimer’s disease. It has created a novel retinal imaging technology that allows for early detection and monitoring of amyloid-beta plaque accumulation in the brain through noninvasive eye imaging. This technology is currently being utilized in various clinical trials worldwide. Additionally, NeuroVision provides data aggregation services, biostatistics, and machine learning applications to analyze large datasets of images and biomarker data, aiming to enhance the understanding of neurodegenerative diseases. The company's services cater to clients both in the United States and internationally.
Syndesi Therapeutics SA is a biopharmaceutical company based in Louvain-la-Neuve, Belgium, founded in 2018. The company focuses on developing drug molecules that modulate the synaptic vesicle protein SV2A, which is crucial for synaptic transmission—the process that facilitates communication between neurons in the brain. By regulating this transmission, Syndesi aims to create effective treatments for Alzheimer’s Disease and other cognitive impairment disorders. The company holds an exclusive license to its innovative platform technology from UCB, a leader in SV2A research. Through its efforts, Syndesi Therapeutics seeks to provide healthcare providers with advanced therapeutic options for managing these challenging conditions.
On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010 and is based in Northbrook, Illinois.
Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.
Cala Health, Inc. is a bioelectronic medicine company focused on developing innovative therapies for chronic diseases. Based in Burlingame, California, the company specializes in wearable neuromodulation devices that utilize advancements in neuroscience and technology to provide individualized peripheral nerve stimulation. Its flagship product, Cala Trio, is a non-invasive therapy designed to offer relief from hand tremors in adults with essential tremor, a condition affecting millions. In addition to its current offerings, Cala Health is actively developing new therapeutic solutions in the fields of neurology, cardiology, and psychiatry, aiming to enhance the standard of care for patients with chronic conditions. Founded in 2013, the company has garnered support from prominent investors in both the healthcare and technology sectors.